Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis

Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis

<p>Abstract</p> <p>Background</p> <p>The efficacy, safety and tolerability of lumiracoxib, a novel selective cyclooxygenase-2 (COX-2) inhibitor, has been demonstrated in previous studies of patients with osteoarthritis (OA). As it is important to establish the long-term...

Full description

Bibliographic Details
Main Authors: Notter Marianne, Patel Neha P, Tannenbaum Hyman, Fleischmann Roy, Sallstig Peter, Reginster Jean-Yves
Format: Article
Language:English
Published: BMC 2008-03-01
Series:BMC Musculoskeletal Disorders
Online Access:http://www.biomedcentral.com/1471-2474/9/32

Similar Items

Similar Items